



September 10, 2014

PerkinElmer Launches Innovative Solaris™ Optical Imaging System

Fluorescence Technology for Small and Large Animal Imaging Advances Translational and Preclinical Research Applications

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer Inc., a global leader focused on the health and safety of people and the environment, today announced the launch of the Solaris™ quantitative optical molecular imaging system. This preclinical solution for use in small and large animal studies will help to advance drug discovery and translational research to develop and validate molecular-guided surgical research protocols.

The Solaris system, when combined with PerkinElmer's suite of fluorescence molecular imaging probes, can bridge molecular imaging research techniques to support potential clinical outcomes. By distinguishing healthy versus diseased tissue in real-time, researchers can more accurately and completely map tumors.

"The Solaris system is our latest breakthrough translational quantitative imaging solution designed to facilitate disease studies and advance next-generation, molecular-level surgical support research," said Brian Kim, President, Life Sciences & Technology, PerkinElmer. "Translational drug discovery validation in large animal models enhances toxicity and efficacy predictability in humans and provides critical knowledge for drug development programs."

The Solaris system is designed for ambient lighting conditions found in preclinical surgical research suites and can dynamically use a broad and versatile range of fluorescent probes, offering flexibility for translational researchers when targeting diseases. Its research applications include drug efficacy, drug safety, measurement of real-time biological therapeutic responses, and advanced molecular-guided surgery applications such as surgical tumor margin determination in live animal models.

PerkinElmer will showcase the Solaris system at the World Molecular Imaging Congress (WMIC) 2014 beginning September 17 in Seoul, South Korea. The company will also display the G8 bench-top PET/CT translational imaging system available through its collaboration with Sofie Biosciences, along with its new Quantum™ GX microCT in vivo imaging system and selected additional PerkinElmer optical in vivo imaging systems.

For more information on PerkinElmer's Solaris system, please visit our [website](#).

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately \$2.2 billion in 2013, has about 7,600 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in

the supply of raw materials and supplies; (11) the manufacture and sale of products exposing us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems; (18) our ability to obtain future financing; (19) restrictions in our credit agreements; (20) our ability to realize the full value of our intangible assets; (21) significant fluctuations in our stock price; (22) reduction or elimination of dividends on our common stock; and (23) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Contacts

Media Contact:

Ilene Schneider, +1 (949) 786-6270 or +1 (949) 433-6862
ilenschneider@aol.com